NCT03806530View on ClinicalTrials.gov

DIalysis Symptom COntrol-Restless Legs Syndrome Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 1, 2019

Primary Completion Date

December 14, 2021

Study Completion Date

July 19, 2022

Conditions
End Stage Renal DiseaseRestless Legs Syndrome
Interventions
DRUG

Gabapentin

100 mg capsule

DRUG

Ropinirole

0.50 mg capsule

DRUG

Placebo Gabapentin

Placebo capsule

DRUG

Placebo Ropinirole

Placebo capsule

Trial Locations (3)

B3H 2Y9

Nova Scotia Health Authority, Halifax

L8N 4A6

St. Joseph's Hamilton Healthcare, Hamilton

K1H 7W9

The Ottawa Hospital, Ottawa

Sponsors
All Listed Sponsors
lead

Population Health Research Institute

OTHER